Sources: Genzyme proposes contingent-value deal for sale of shares

11/22/2010 | Wall Street Journal, The

Genzyme, which continues to reject a $69-per-share bid by Sanofi-Aventis, is considering using a contingent-value right, a deal structure that might end the takeover deadlock, sources said. The structure gives shareholders a financial benefit if the acquired company reaches certain milestones. Genzyme reportedly is also integrating the structure in talks with other potential buyers.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park